FDA warns Insung Medical over unreported ANKOR Endobronchial Tube malfunction and inadequate MDR procedures.
What happened
FDA inspected the company’s Gangwon, Korea facility from April 28, 2025, through May 1, 2025. FDA found the company did not report a complaint that an ANKOR Endobronchial Tube’s carinal cuff failed to inflate during a pre-use check, even though the company learned of the event on May 9, 2022. FDA also found the company’s Medical Device Reporting (MDR) procedure—the written steps for identifying and reporting device problems—lacked required definitions and instructions for completing and submitting reports.
What FDA found
The company did not report a complaint that an ANKOR Endobronchial Tube’s carinal cuff failed to inflate during a pre-use check within 30 calendar days after learning of it on May 9, 2022.
21 CFR 803.50(a)(2); 21 CFR 803.12(a)The company’s written MDR procedure did not define key terms such as “become aware,” “malfunction,” “serious injury,” and “reasonably suggests,” which are needed to decide whether an event must be reported.
21 CFR 803.17(a)(1); 21 CFR 803.3; 21 CFR 803.20(c)(1)The company’s MDR procedure did not explain how to complete the FDA 3500A form or how to ensure all known information is submitted for each event.
21 CFR 803.17(a)(3)The company’s MDR procedure did not describe when to submit supplemental or follow-up reports or what those reports must contain.
21 CFR 803.17(a)(3); 21 CFR 803.56
What FDA wants
FDA asks the company to reply in writing within 15 business days describing the specific steps taken to address the violations, how it will prevent recurrence, and documentation of corrections or corrective actions, including a timetable if actions will take longer.
Who should pay attention
- makers of life-supporting airway devices
- companies that buy or distribute endobronchial tubes
- quality teams handling device complaints and MDR reporting
This is a summary. Read the original letter on fda.gov.